Trial Profile
A Multicenter, Randomized, Double-blind, Fixed-dose, 6-week Trial of the Efficacy and Safety of Asenapine Compared With Placebo in Subjects With an Acute Exacerbation of Schizophrenia (Phase 3 ; P06124)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Asenapine (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme; Organon
- 15 Dec 2020 According to a Noven Pharmaceuticals media release, data from this study are published in the January/February 2021 edition of the Journal of Clinical Psychiatry.
- 15 Dec 2020 Results presented in a Noven Pharmaceuticals media release.
- 25 Apr 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.